Bacthera is a leading CDMO in live biotherapeutic products (LBPs) with 3 manufacturing sites and expertise in microbiology, processes, and innovation. They provide end-to-end development and manufacturing services from pre-clinical through commercialization. Bacthera was established in 2014 through a collaboration between Chr. Hansen and Lonza combining their complementary LBP expertise.

1. Bacthera Company Presentation October 2020

2. PAGE 2
We are a leading CDMO in the LBP
industry, supporting our customers
with microbiology know-how,
process expertise and industry
changing innovation

3. PAGE
BACTHERA AT A GLANCE
3
3 manufacturing
sites in DK & CH
67 employees
+123% growth
Industry changing
innovation
From lab-to-
market services

4. PAGE
OUR HERITAGE
4
– World-leading know how in manufacturing &
processing living microbes
– Extensive strain-, growth media- and cryo-libraries
– Innovative drug substance downstream processes
– Leading in analytical characterization of bacteria
– Highest quality standards & world-leading know-how in
GMP manufacturing
– World’s only capsule with enteric attributes (enTRinsic®)
– (Large-scale) commercialization options (e.g. IBEX®)
– Access to global manufacturing presence (e.g. USA,
China, etc.)
– Best-practice CDMO principles

5. PAGE
OUR JOURNEY
5
Chr. Hansen & Lonza saw
opportunity to join forces
and establish Bacthera
New management
appointed
Foundation of Bacthera:
Chr. Hansen & Lonza
know-how, teams &
assets transferred. First
operation started.
2019 2020 2021
Expanding operational &
commercial readiness
GMP certifications of
DK and CH sites
Chr. Hansen & Lonza
had complementary
expertise in the LBP
industry
2014

6. PAGE
END-TO-END SOLUTIONS DELIVERED FROM OUR SITES
6
Copenhagen, Denmark
Basel, Switzerland
Visp*, Switzerland
– Drug Substance manufacturing
– Clinical & commercial supply
– Head Quarter
– Drug Product manufacturing
– Packaging
– Clinical & small-scale
commercial supply
– Operational from 2022
– Drug Substance & Drug
Product manufacturing
– Packaging & Serialization
– (Large scale-) Commercial
supply
*Site operated by Lonza, Bacthera
has access to the IBEX® complex
for commercial production.
Workspace to be set-up yet

7. PAGE
CONTRIBUTION TO YOUR LBP JOURNEY
7
From lab-to-market:
Drug
discovery
Pre-
clinical
Phase I Phase II Phase III
Approval &
Commercial
Bacthera offers CMC development services and supply of Drug Substance &
Drug Product for (pre-)clinical studies and commercial demand.

8. PAGE
CONTRIBUTION TO YOUR LBP JOURNEY
8
Bacthera will manufacture cell banks and develop the DS & DP processes
interdependently with strong analytics package embedded, resulting in
the best possible product for the customer’s development journey
Pre-
clinical
Phase I Phase II Phase III
Approval &
commercial
Cell banking &
early stage process and
analytical development
(DS & DP)
Commercial
supply
Customer
Late stage process
& analytical dev.
(DS & DP)
Process
validation
Reg.
filing
PC-
supply
PI supply
PII
supply
PIII
supply
Analytical validation
Manufacturing
Development

9. PAGE
Integrated
DS/DP &
analytical
development
Strong
microbiology
& process
expertise
VALUE CONTRIBUTION TO YOUR LBP JOURNEY
9
first time
right
+
fast
delivery
From lab-to-
market:
One-stop
CDMO

10. PAGE
WE CAN WORK WITH
10
Strict & facultative
anaerobes
BSL 1/2 GMO’s

11. PAGE 11
Strain intake
& Cell
Banking
DS
Development
DP
Development
DS Production
Analytical
Development
DS+DP
DP Production
Packaging
Shipment to customer
QC & QA Release
Stability
OUR SERVICES IN PRODUCT DEVELOPMENT

12. PAGE 12
Large-scale manufacturing in
Lonza IBEX® complex in Visp (CH)*
up to 20’000 L
fermenters
up to 150’000
capsules/h
- 30 months
time-to-market**
globally scalable concept
- 30%
CapEx spending**
used & well-known by global
pharma players (e.g. Sanofi)
*Site operated by Lonza, Bacthera has access to the IBEX® complex
for commercial production. Workspace to be set-up yet.
**compared to a typical industry approach
OUR COMMERCIAL MANUFACTURING SOLUTION

13. PAGE
OUR LEADERSHIP IN INNOVATION
13
Strains,
Media & Cryo
AnalyticsDrying
Bacthera’s customers can benefit from a variety of innovations, technologies and
background know-how that can make the essential difference in drug development &
registration
enTRinsic®

14. PAGE
WHY WORK WITH BACTHERA?
14
Well-established
expertise in LBP
manufacturing
Right first time,
from pre-clinical
to commercial
Winning
innovations &
technologies
World-class
experts & work
mentality

15. PAGE
YOUR CONTACTS WITHIN BACTHERA
15
Felix Faupel
Chief Commercial
Officer
ffel@bacthera.com
Alain Heron
Head of Commercial
Development
alhe@bacthera.com
Gemma Henderson
Head of Project &
Portfolio Management
gehe@bacthera.com